PHANES THERAPEUTICS entered into a research collaboration with Xyphos Biosciences, Inc., an Astellas Company
The strategic research collaboration and license agreement is between Xyphos Biosciences, which sold up to Astellas for $120 million upfront late in 2019, and GO. Xyphos is a West Coast biotech that is built on a technology for controlling cell therapies. The resulting convertibleCAR cells have modified NKG2D receptors designed to enable physicians to control their activity using engineered molecules such as bispecific antibodies.
VIVEbiotech, S.L., a gene transfer technologies Contract Development and Manufacturing Organization (CDMO) developing and GMP manufacturing lentiviral vectors, today announces a collaboration with Xyphos Biosciences. The collaboration will concentrate on the development and manufacturing of GMP-grade lentiviral vectors.